FDA Approves Tracer That Improves Detection of Advanced Prostate Cancer
Tracer is injected into the bloodstream and lights up metastatic prostate cancer cells during PET scan
FRIDAY, May 28, 2021 (HealthDay News) -- A new imaging agent that detects prostate cancer that has spread to other parts of the body has been approved by the U.S. Food and Drug Administration.
The tracer will help doctors find metastatic prostate cancer cells that are difficult to detect with traditional imaging methods, Michael Morris, M.D., a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City who was involved in clinical trials of the tracer, told NBC News.
He noted that when prostate cancer spreads, it often goes into the bones and it is "really hard to take pictures of what's going on inside of bone." With the new tracer, we "can detect it much more clearly and much earlier than we could before," he told NBC News.
The tracer from medical imaging company Lantheus is injected into the bloodstream and lights up metastatic prostate cancer cells during a positron emission tomography scan.
The new tracer -- the first for advanced prostate cancer that is commercially available across the United States -- is not meant to replace the prostate-specific antigen blood test, NBC News reported.